Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
06 nov. 2018 07h00 HE
|
Ritter Pharmaceuticals, Inc.
Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019...
Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance
22 mai 2018 08h30 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split
22 mars 2018 11h35 HE
|
Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that...
Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
19 mars 2018 06h35 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, March 19, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate...
Chapman Global Medical Center Achieves National Accreditation and Recognition for Metabolic and Bariatric Surgery
08 mars 2018 05h00 HE
|
KPC Healthcare Inc.
Orange County, CA, March 08, 2018 (GLOBE NEWSWIRE) -- Patients seeking surgical treatment for severe obesity and its related conditions have a high-quality choice for receiving treatment. Chapman...
Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial
29 janv. 2018 09h00 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutics that modulate the human gut...
MicroBiome Therapeutics Completes Series B Financing and Prepares to Launch First Microbiome Modulator Product
01 nov. 2017 07h00 HE
|
MicroBiome Therapeutics, LLC
NEW ORLEANS, La., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MicroBiome Therapeutics, LLC (MBT), a leading company applying the science of the gastrointestinal (GI) microbiome to promote health and wellness,...
Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
31 oct. 2017 06h45 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering
29 sept. 2017 08h00 HE
|
Ritter Pharmaceuticals
Los Angeles, California, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Clinical "CSI" for Your Body
11 févr. 2008 10h30 HE
|
LaValle Metabolic Institute
CINCINNATI, OH--(Marketwire - February 11, 2008) - Don't beat yourself up if your resolution to
lose a few pounds fails. It may not be your fault.
Metabolic expert Jim LaValle says if you've always...